CN1073103C - 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 - Google Patents

用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 Download PDF

Info

Publication number
CN1073103C
CN1073103C CN97196877A CN97196877A CN1073103C CN 1073103 C CN1073103 C CN 1073103C CN 97196877 A CN97196877 A CN 97196877A CN 97196877 A CN97196877 A CN 97196877A CN 1073103 C CN1073103 C CN 1073103C
Authority
CN
China
Prior art keywords
base
compound
alkylidene group
inferior
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN97196877A
Other languages
English (en)
Chinese (zh)
Other versions
CN1226892A (zh
Inventor
杰弗里·M·登纳
伊莱恩·伊玲·库
肯·D·赖斯
维维安·鲁然·旺
温迪·贝思·扬
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Axys Pharmaceuticals Inc
Original Assignee
Arris Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arris Pharmaceutical Corp filed Critical Arris Pharmaceutical Corp
Publication of CN1226892A publication Critical patent/CN1226892A/zh
Application granted granted Critical
Publication of CN1073103C publication Critical patent/CN1073103C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/06—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms
    • C07D233/08—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms
    • C07D233/12—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to ring carbon atoms with alkyl radicals, containing more than four carbon atoms, directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D233/14—Radicals substituted by oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN97196877A 1996-07-30 1997-07-30 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物 Expired - Fee Related CN1073103C (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US2313996P 1996-07-30 1996-07-30
US60/023,139 1996-07-30
US89577297A 1997-07-17 1997-07-17
US08/895,772 1997-07-17

Publications (2)

Publication Number Publication Date
CN1226892A CN1226892A (zh) 1999-08-25
CN1073103C true CN1073103C (zh) 2001-10-17

Family

ID=26696778

Family Applications (1)

Application Number Title Priority Date Filing Date
CN97196877A Expired - Fee Related CN1073103C (zh) 1996-07-30 1997-07-30 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物

Country Status (17)

Country Link
EP (1) EP0934293A1 (lv)
JP (1) JP2001509787A (lv)
KR (1) KR20000029679A (lv)
CN (1) CN1073103C (lv)
AU (1) AU733621B2 (lv)
CA (1) CA2262542A1 (lv)
CZ (1) CZ29799A3 (lv)
EE (1) EE9900036A (lv)
FI (1) FI990171A (lv)
HU (1) HUP0003267A3 (lv)
LV (1) LV12291B (lv)
NO (1) NO990433L (lv)
NZ (1) NZ333713A (lv)
PL (1) PL331465A1 (lv)
SI (1) SI9720047A (lv)
SK (1) SK8599A3 (lv)
WO (1) WO1998004537A1 (lv)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6221914B1 (en) 1997-11-10 2001-04-24 Array Biopharma Inc. Sulfonamide bridging compounds that inhibit tryptase activity
JP2002502845A (ja) * 1998-02-06 2002-01-29 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ トリプターゼ阻害物質
US6489327B1 (en) * 1998-02-06 2002-12-03 Max-Planck-Gesellschaft Zur Fordrungder Wisenschaften, E.V. Tryptase inhibitors
CA2342855A1 (en) * 1998-09-04 2000-03-16 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel pyranoses
AU777026B2 (en) * 1999-08-10 2004-09-30 Altana Pharma Ag Novel tryptase inhibitors
WO2001019809A1 (en) * 1999-09-14 2001-03-22 Byk Gulden Lomberg Chemische Fabrik Gmbh Tryptase inhibitors
AU1413301A (en) * 1999-11-17 2001-05-30 Sumitomo Pharmaceuticals Company, Limited Diabetic remedy containing dipiperazine derivative
DE19955476A1 (de) * 1999-11-18 2001-05-23 Boehringer Ingelheim Pharma Bis-basische Verbindungen als Tryptase-Inhibitoren, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
DE60011677T2 (de) * 1999-12-20 2005-07-14 Altana Pharma Ag Tryptase-inhibitoren
ATE268322T1 (de) 1999-12-20 2004-06-15 Altana Pharma Ag Inhibitoren der tryptase
US6924305B2 (en) 2001-01-31 2005-08-02 Altana Pharma Ag Diazocine derivatives and their use as tryptase inhibitors
WO2002066420A2 (en) * 2001-02-21 2002-08-29 Altana Pharma Ag Tryptase inhibitors
DE60217076T2 (de) 2001-02-21 2007-06-21 Altana Pharma Ag Tryptaseinhibitoren
AU2002254941B2 (en) * 2001-03-15 2007-05-17 Altana Pharma Ag Tryptase-inhibitors
WO2002074732A2 (en) * 2001-03-15 2002-09-26 Altana Pharma Ag Tryptase-inhibitors
US6818787B2 (en) 2001-06-11 2004-11-16 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US7186855B2 (en) 2001-06-11 2007-03-06 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
KR100958552B1 (ko) 2001-06-11 2010-05-17 제노포트 인코포레이티드 Ｇａｂａ 유사체의 프로드러그, 이의 조성물 및 용도
AU2002314165B2 (en) 2001-06-19 2008-02-21 Altana Pharma Ag Tryptase inhibitors
CN102429882B (zh) 2004-11-04 2015-03-25 什诺波特有限公司 加巴喷丁前体药物持续释放口服剂型
TWI432188B (zh) 2008-12-19 2014-04-01 Merz Pharma Gmbh & Co Kgaa 供治療發炎性皮膚疾病之１－胺基－烷基環己烷衍生物類
CN102159201A (zh) 2008-12-19 2011-08-17 莫茨药物股份两合公司 用于治疗肥大细胞介导的疾病的1-氨基-烷基环己烷衍生物
FR3038605B1 (fr) 2015-07-06 2018-08-24 Universite Amiens Picardie Jules Verne Diamines primaires vicinales associees a des motifs chelateurs de metaux et/ou de radicaux libres, actives contre les stress carbonyle et oxydant et leur utilisation
JP7373191B2 (ja) * 2017-05-12 2023-11-02 国立研究開発法人理化学研究所 クラスａ ｇｐｃｒ結合性化合物改変体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4845242A (en) * 1987-04-28 1989-07-04 Georgia Tech Research Corporation Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents
CZ289930B6 (cs) * 1993-03-12 2002-04-17 Axys Pharmaceuticals, Inc. Arylové a heteroarylové peptidové deriváty a farmaceutické prostředky je obsahující
US5525623A (en) * 1993-03-12 1996-06-11 Arris Pharmaceutical Corporation Compositions and methods for the treatment of immunomediated inflammatory disorders
PL322409A1 (en) * 1995-03-24 1998-01-19 Arris Pharm Corp Reversible protease inhibitors
TW438591B (en) * 1995-06-07 2001-06-07 Arris Pharm Corp Reversible cysteine protease inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995032945A1 (en) * 1994-06-01 1995-12-07 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell mediated conditions
WO1996009297A1 (en) * 1994-09-23 1996-03-28 Arris Pharmaceutical Corporation Compositions and methods for treating mast-cell inflammatory condition

Also Published As

Publication number Publication date
CA2262542A1 (en) 1998-02-05
CN1226892A (zh) 1999-08-25
SI9720047A (sl) 1999-08-31
LV12291B (lv) 2000-04-20
FI990171A0 (fi) 1999-01-29
KR20000029679A (ko) 2000-05-25
PL331465A1 (en) 1999-07-19
AU3967097A (en) 1998-02-20
AU733621B2 (en) 2001-05-17
HUP0003267A3 (en) 2002-02-28
FI990171A (fi) 1999-03-23
NO990433D0 (no) 1999-01-29
EE9900036A (et) 1999-08-16
HUP0003267A2 (hu) 2001-06-28
JP2001509787A (ja) 2001-07-24
EP0934293A1 (en) 1999-08-11
WO1998004537A1 (en) 1998-02-05
NZ333713A (en) 2000-12-22
LV12291A (lv) 1999-06-20
CZ29799A3 (cs) 1999-06-16
SK8599A3 (en) 2000-03-13
NO990433L (no) 1999-03-25

Similar Documents

Publication Publication Date Title
CN1073103C (zh) 用于治疗与类胰蛋白酶活性有关的疾病的新化合物和组合物
CN1143855C (zh) 作为抗凝剂的邻氨基苯甲酰胺衍生物
CN1107061C (zh) 趋化细胞因子受体－3拮抗剂
CN1077573C (zh) 用作神经激肽拮抗剂的杂环类化合物
CN1036918C (zh) 苯并吡喃衍生物及含有此衍生物的k+通道活化剂
CN1329596A (zh) 吡啶甲酰胺衍生物、含有其作为有效成分的有害生物防除剂
CN1115982A (zh) 具有药理学活性的吡啶类衍生物及其制备方法
CN1254337A (zh) N－羟基4－磺酰基丁酰胺化合物
CN1040986A (zh) 环烷基取代的戊二酰胺衍生物的制备
CN1088917A (zh) 取代的苄氨基含氮非芳族杂环化合物
CN1431999A (zh) 具有血管损伤活性的吲哚衍生物
CN1330637A (zh) 用于治疗炎性疾病的化合物
CN1268116A (zh) 3－脒基苯胺衍生物,活化血凝固因子x抑制剂和制备这些物质的中间体
CN1098094A (zh) 芳基取代的杂环
CN1871244A (zh) 作为腺苷受体配体的噻唑并吡啶衍生物
CN1688555A (zh) 新的二环类激素敏感性脂酶抑制剂
CN1253555A (zh) 新的2－(亚氨基甲基)氨基－苯基衍生物,其制备方法、作为药物的应用及其药物组合物
CN1198827C (zh) 精选的K－252a衍生物
CN1278790A (zh) 化合物
CN1211232A (zh) 用氨基酸和羟基酸衍生物取代的苄脒衍生物和其作为抗凝血剂的用途
CN1658877A (zh) 碱性非肽缓激肽拮抗剂及其药物组合物
CN1150162C (zh) 联苯基脒衍生物
CN1181069A (zh) 作为速激肽受体拮抗剂的5－(4－取代的哌啶基－1)－3－芳基戊酸衍生物
CN1753891A (zh) Ccr－3受体拮抗剂
CN1458922A (zh) 尿素衍生物及以其作为有效成分的粘连分子阻断剂

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: AXYS PHARMACEUTICAL CORPORATION

Free format text: FORMER NAME OR ADDRESS: ARRIS PHARMACEUTICAL CORPORATION

CP01 Change in the name or title of a patent holder

Patentee after: AXYS Pharmaceuticals, Inc.

Patentee before: Arris Pharmaceutical Corp.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee